Jacobsen et al. reported a case of RDD with KRAS mutation successfully treated with cobimetinib, a MEK inhibitor, which provided further support of the importance of the MAPK/ERK pathway in RDD [33]. Here, MAP2K7 is linked to sinus histiocytosis with massive lymphadenopathy.